Exceptional response to cyclophosphamide and dexamethasone in a patient with metastatic castrate-resistant prostate cancer and RB1 mutation.

Dohogne, Briana; Arif-Tiwari, Hina; Bracamonte, Erika; Babiker, Hani M

Dohogne, Briana; Arif-Tiwari, Hina; Bracamonte, Erika; Babiker, Hani M.

Affiliation

Dohogne B; University of Arizona College of Medicine.
Arif-Tiwari H; Departments of Medical Imaging.
Bracamonte E; Pathology.
Babiker HM; Hematology and Oncology, University of Arizona College of Medicine, Tucson, Arizona, USA.

Anticancer Drugs ; 32(3): 337-343, 2021 03 01.

Article in En | MEDLINE | ID: mdl-33534414

Subject(s)

Cyclophosphamide/therapeutic use; Dexamethasone/therapeutic use; Prostatic Neoplasms, Castration-Resistant/drug therapy; Aged, 80 and over; Cyclophosphamide/administration & dosage; Dexamethasone/administration & dosage; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant/genetics; Prostatic Neoplasms, Castration-Resistant/pathology; Retinoblastoma Binding Proteins/genetics; Ubiquitin-Protein Ligases/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dexamethasone / Cyclophosphamide / Prostatic Neoplasms, Castration-Resistant Type of study: Prognostic_studies Limits: Aged80 / Humans / Male Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google